Reappraisal of glucocorticoids in castrate-resistant prostate cancer

Asian Journal of Andrology

Volumn 16, Issue 5, 2014, Pages 666-

  Sartor, Oliver ^a   Parker, Christopher C ^b   De Bono, Johann ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DEXAMETHASONE; ENZALUTAMIDE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PROSTATE SPECIFIC ANTIGEN; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; PHENYLTHIOHYDANTOIN;

CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; HUMAN; IN VITRO STUDY; NONHUMAN; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG RESISTANCE; MALE; METABOLISM; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, GLUCOCORTICOID;

EID: 84907015314     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.133314     Document Type: Short Survey

References (10)

1. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-22.
2. Sharifi N. Steroid receptors aplenty in prostate cancer. N Engl J Med 2014; 370: 970-1.
3. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996; 47: 61-9.
4. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 2008; 101: 1084-9.
5. Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, et al. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer 2011; 104: 620-8.
6. Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998; 52: 252-6.
7. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995; 76: 453-62.
8. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-7.
9. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8: 597-610.
10. Lorente D, Weatherstone K, Omlin A, Pezaro C, Ferraldeschi R, et al. Tumor responses after steroid switch of prednisolone (P) to dexamethasone (D) in castration-resistant prostate cancer (CRPC) patients (pts) on abiraterone acetate (AA). European Cancer Congress; 2013. [Abstract 2918].